Published in Cell Microbiol on August 11, 2015
Depletion of UDP-Glucose and UDP-Galactose Using a Degron System Leads to Growth Cessation of Leishmania major. PLoS Negl Trop Dis (2015) 1.41
The Roles of Mast Cells in Parasitic Protozoan Infections. Front Immunol (2017) 0.78
Escaping Deleterious Immune Response in Their Hosts: Lessons from Trypanosomatids. Front Immunol (2016) 0.76
Kinetoplastid Membrane Protein-11 as a Vaccine Candidate and a Virulence Factor in Leishmania. Front Immunol (2015) 0.76
Immune responses against protozoan parasites: a focus on the emerging role of Nod-like receptors. Cell Mol Life Sci (2016) 0.75
Critical role of caspase-8-mediated IL-1 signaling in promoting Th2 responses during asthma pathogenesis. Mucosal Immunol (2016) 0.75
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell (2002) 20.11
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
Leishmaniasis worldwide and global estimates of its incidence. PLoS One (2012) 18.07
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 14.80
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 9.77
Cutaneous leishmaniasis. Lancet Infect Dis (2007) 9.32
Advances in leishmaniasis. Lancet (2005) 8.95
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol (2002) 6.59
The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol (2011) 5.73
Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med (1998) 3.68
A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol (2000) 3.47
Complement and its role in innate and adaptive immune responses. Cell Res (2009) 3.07
Clinical spectrum of Leishmaniasis. Clin Infect Dis (1996) 2.94
Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol (2011) 2.93
The mouse macrophage receptor for C3bi (CR3) is a major mechanism in the phagocytosis of Leishmania promastigotes. J Immunol (1985) 2.63
Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol (2002) 2.18
Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc Natl Acad Sci U S A (2000) 2.11
Mechanism of lethal effect of human serum upon Leishmania donovani. J Immunol (1980) 2.08
Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol (2003) 2.08
Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol (2003) 1.91
Persistence without pathology in phosphoglycan-deficient Leishmania major. Science (2003) 1.89
The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci U S A (2003) 1.89
MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol (2003) 1.82
Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. J Immunol (1995) 1.77
Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther (2009) 1.75
Developmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage. EMBO J (1992) 1.75
The role of phosphoglycans in Leishmania-sand fly interactions. Proc Natl Acad Sci U S A (2000) 1.68
Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages. J Immunol (1984) 1.66
Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun (2004) 1.65
Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol Biochem Parasitol (2002) 1.65
Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med (2006) 1.59
NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. J Exp Med (2007) 1.57
Macrophage activation to kill Leishmania tropica: defective intracellular killing of amastigotes by macrophages elicited with sterile inflammatory agents. J Immunol (1984) 1.54
Complement binding by two developmental stages of Leishmania major promastigotes varying in expression of a surface lipophosphoglycan. J Exp Med (1988) 1.51
Evidence that Leishmania donovani utilizes a mannose receptor on human mononuclear phagocytes to establish intracellular parasitism. J Immunol (1986) 1.47
Inflammasome-derived IL-1β production induces nitric oxide-mediated resistance to Leishmania. Nat Med (2013) 1.46
Disruption of mannose activation in Leishmania mexicana: GDP-mannose pyrophosphorylase is required for virulence, but not for viability. EMBO J (2001) 1.46
TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur J Immunol (2007) 1.46
RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages. Eur J Immunol (2006) 1.41
Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol (1999) 1.32
Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice. J Biol Chem (2000) 1.28
Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med (2003) 1.26
Distinct roles for MyD88 and Toll-like receptor 2 during Leishmania braziliensis infection in mice. Infect Immun (2009) 1.24
Lipophosphoglycan is not required for infection of macrophages or mice by Leishmania mexicana. EMBO J (2000) 1.23
Malaria surveillance--United States, 2011. MMWR Surveill Summ (2013) 1.23
Leishmaniasis Vaccine: Where are We Today? J Glob Infect Dis (2010) 1.22
Down-regulation of dendritic cell signaling pathways by Leishmania amazonensis amastigotes. Mol Immunol (2008) 1.20
Comparisons of mutants lacking the Golgi UDP-galactose or GDP-mannose transporters establish that phosphoglycans are important for promastigote but not amastigote virulence in Leishmania major. Infect Immun (2007) 1.19
Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9. J Immunol (1990) 1.17
Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol (2010) 1.14
High levels of susceptibility and T helper 2 response in MyD88-deficient mice infected with Leishmania major are interleukin-4 dependent. Infect Immun (2003) 1.10
Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol Med (2014) 1.09
Binding and release of C3 from Leishmania donovani promastigotes during incubation in normal human serum. J Immunol (1989) 1.08
Leishmania species: mechanisms of complement activation by five strains of promastigotes. Exp Parasitol (1986) 1.07
Recognition of the major cell surface glycoconjugates of Leishmania parasites by the human serum mannan-binding protein. Mol Biochem Parasitol (1994) 1.04
Infection of C57BL/10ScCr and C57BL/10ScNCr mice with Leishmania major reveals a role for Toll-like receptor 4 in the control of parasite replication. J Leukoc Biol (2004) 1.02
The major surface protein of Leishmania promastigotes is a fibronectin-like molecule. Eur J Immunol (1988) 1.02
An NLRP3 inflammasome-triggered Th2-biased adaptive immune response promotes leishmaniasis. J Clin Invest (2015) 1.01
Host genetic background determines whether IL-18 deficiency results in increased susceptibility or resistance to murine Leishmania major infection. Immunol Lett (2004) 0.98
Leishmania donovani exploits host deubiquitinating enzyme A20, a negative regulator of TLR signaling, to subvert host immune response. J Immunol (2012) 0.98
Role of Toll-like receptor 9 signaling in experimental Leishmania braziliensis infection. Infect Immun (2013) 0.97
Killing of Leishmania tropica amastigotes by factors in normal human serum. J Immunol (1984) 0.97
Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J Immunol (2000) 0.95
Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses. Clin Exp Immunol (2013) 0.93
IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice. Int Immunol (2010) 0.92
Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect Immun (2011) 0.91
Histopathological analysis of initial cellular response in TLR-2 deficient mice experimentally infected by Leishmania (L.) amazonensis. Int J Exp Pathol (2010) 0.90
Complement interaction with trypanosomatid promastigotes in normal human serum. J Exp Med (2002) 0.90
Effect of immunoglobulin M from normal human serum on Leishmania donovani promastigote agglutination, complement-mediated killing, and phagocytosis by human monocytes. Infect Immun (1989) 0.89
IL-1 signalling is dispensable for protective immunity in Leishmania-resistant mice. Exp Dermatol (2010) 0.88
Leishmania inhibitor of serine peptidase 2 prevents TLR4 activation by neutrophil elastase promoting parasite survival in murine macrophages. J Immunol (2010) 0.88
TLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasis. PLoS Pathog (2012) 0.87
C3 receptors on macrophages. J Cell Sci Suppl (1988) 0.86
Differences in human macrophage receptor usage, lysosomal fusion kinetics and survival between logarithmic and metacyclic Leishmania infantum chagasi promastigotes. Cell Microbiol (2009) 0.86
Toll-like receptors and CD40 modulate each other's expression affecting Leishmania major infection. Clin Exp Immunol (2014) 0.85
UNC93B1 and nucleic acid-sensing Toll-like receptors mediate host resistance to infection with Leishmania major. J Biol Chem (2013) 0.85
Complement receptor 3 deficiency influences lesion progression during Leishmania major infection in BALB/c mice. Infect Immun (2009) 0.85
Interleukin-18 enhances a Th2 biased response and susceptibility to Leishmania mexicana in BALB/c mice. Microbes Infect (2008) 0.85
Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver. Infect Immun (2013) 0.85
Coinjection with TLR2 agonist Pam3CSK4 reduces the pathology of leishmanization in mice. PLoS Negl Trop Dis (2015) 0.85
Leishmania donovani targets tumor necrosis factor receptor-associated factor (TRAF) 3 for impairing TLR4-mediated host response. FASEB J (2014) 0.82
TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis. Eur J Immunol (2012) 0.80
PKC/ROS-Mediated NLRP3 Inflammasome Activation Is Attenuated by Leishmania Zinc-Metalloprotease during Infection. PLoS Negl Trop Dis (2015) 0.80
Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletion. Infect Immun (2013) 0.79
The inflammasome: firing up innate immunity. Immunol Rev (2015) 0.78
The role of complement in the early phase of Leishmania (Leishmania) amazonensis infection in BALB/c mice. Braz J Med Biol Res (2004) 0.76
Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex. J Immunol (1985) 0.76
Differential surface deposition of complement proteins on logarithmic and stationary phase Leishmania chagasi promastigotes. J Parasitol (2012) 0.75
ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci Immunol (2016) 0.92
Chronic TLR Stimulation Controls NLRP3 Inflammasome Activation through IL-10 Mediated Regulation of NLRP3 Expression and Caspase-8 Activation. Sci Rep (2015) 0.89
DOCK2 confers immunity and intestinal colonization resistance to Citrobacter rodentium infection. Sci Rep (2016) 0.75
Distinct role of IL-1β in instigating disease in Sharpin(cpdm) mice. Sci Rep (2016) 0.75